OMEROS CORP Proceeds from Debt, Net of Issuance Costs
OMEROS CORP (OMER) reported Proceeds from Debt, Net of Issuance Costs of $225.03 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-01.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2022-03-01
- OMEROS CORP proceeds from debt, net of issuance costs for the quarter ending 2020-12-31 was $0.00.
- OMEROS CORP proceeds from debt, net of issuance costs for fiscal 2020 was $225.03M.
- OMEROS CORP proceeds from debt, net of issuance costs for fiscal 2018 was $210.00M.
| Period end | Proceeds from Debt, Net of Issuance Costs 3 month | Proceeds from Debt, Net of Issuance Costs 9 month | Proceeds from Debt, Net of Issuance Costs 9 month as first filed | Proceeds from Debt, Net of Issuance Costs 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $225.03M 10-K · filed 2022-03-01 | ||
| 2020-09-30 | $225.03M 10-Q · filed 2021-11-09 | $218.25M 10-Q · filed 2020-11-09 | ||
| 2018-12-31 | $210.00M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |